Pfizer boasted that the FDA had granted “priority review” for a drug, crizotinib, that treats some types of lung cancer.

辉瑞（Pfizer）自称已获得食品及药物管理局对药品crizotinib的“优先审核”。 （crizotinib是治疗某些类型肺癌的药品）。

youdao

Pfizer’s crizotinib attacks a protein encoded by a gene found in fewer than 5% of patients with non-small-cell lung cancer.

辉瑞公司的crizotinib攻击某种蛋白质，这种蛋白质由在不到5%的非小细胞肺癌患者中发现的一种基因编码。

youdao

Pfizer's crizotinib attacks a protein encoded by a gene found in fewer than 5% of patients with non-small-cell lung cancer.

Pfizer的crizotinib专门攻击某种基因转录的蛋白，只有少于5%的非小细胞肺癌患者具有这种基因。 Roche的vemurafenib通过阻断基因B-RAF的变异体抵抗晚期黑色素瘤。

youdao

This month Pfizer, an American company, announced that America's Food and drug Administration (FDA) would speed up its review of a cancer drug called crizotinib.

本月美国辉瑞制药公司公布，美国食品及药品管理局(FDA)将加快抗癌药crizotinib的复审速度。

youdao

This month Pfizer, an American company, announced that America's Food and drug Administration (FDA) would speed up its review of a cancer drug called crizotinib.

本月美国辉瑞制药公司公布，美国食品及药品管理局(FDA)将加快抗癌药crizotinib的复审速度。

youdao